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Type 1 and type 2 diabetes mellitus are chronic 
disorders  of  insulin  insufficiency  resulting  in 
the dysregulation of glucose homeostasis, hy-
perglycemia, and vascular complications. Al-
though these two types of diabetes have distinct 
pathogenic mechanisms, a common element 
among both forms is the insufficient functional 
pancreatic -cell mass that is required to main-
tain  euglycemia  (Bach,  1994;  Mathis  et  al., 
2001; Kahn, 2003; Rhodes, 2005). Thus, one 
of the overarching goals in the treatment of all 
types of diabetes is the preservation and growth 
of  cells.
Erythropoietin (EPO) is best known for its 
role in promoting red blood cell formation and 
survival (Krantz, 1991; Lacombe and Mayeux, 
1998). Interestingly, recent studies have shown 
the EPO-R to be present in nonerythroid tis-
sues, including the brain (Digicaylioglu et al., 
1995), heart (Depping et al., 2005), small bowel 
(Juul et al., 1999), uterus (Yasuda et al., 1998), 
kidney (Westenfelder et al., 1999), and pancre-
atic islets (Fenjves et al., 2003). Accordingly, the 
biological effects of EPO in nonerythroid tis-
sues are currently being investigated. In partic-
ular, several studies have shown the efficacy of 
EPO  in  providing  cytoprotection  in  experi-
mental models of tissue injury (for review see 
Brines and Cerami, 2006).
Several lines of evidence have prompted us 
to further investigate the potential cytoprotec-
tive role of EPO in mediating protection from 
diabetes. (a) EPO-R is present in human and 
rodent pancreatic islets (Fenjves et al., 2003). 
Furthermore, EPO overexpression in human   
CORRESPONDENCE  
Minna Woo: 
mwoo@uhnres.utoronto.ca
Abbreviations used: EPO, 
erythropoietin; MLDS, multiple 
low doses of STZ; mRNA, 
messenger RNA; PI3K,  
phosphatidylinositol-3 kinase; 
rHuEPO, recombinant human 
EPO; STZ, streptozotocin; 
TUNEL, terminal deoxynucle-
otidyl transferase dUTP nick 
end labeling; VEGF, vascular 
endothelial growth factor.
Erythropoietin protects against diabetes 
through direct effects on pancreatic  cells
Diana Choi,1,2 Stephanie A. Schroer,2 Shun Yan Lu,2 Linyuan Wang,2,3 
Xiaohong Wu,2 Yunfeng Liu,5,6 Yi Zhang,5,6 Herbert Y. Gaisano,5,6  
Kay-Uwe Wagner,7,8 Hong Wu,9 Ravi Retnakaran,1,4,5,10  
and Minna Woo1,2,3,4,5,11,12
1Institute of Medical Science; 2Ontario Cancer Institute; 3Department of Medical Biophysics; 4Division of Endocrinology and 
Metabolism, 5Department of Medicine; and 6Department of Physiology, University of Toronto, Toronto, Ontario M5S 1A1, Canada
7Eppley Institute for Research in Cancer and Allied Diseases and 8Department of Pathology and Microbiology,  
University of Nebraska Medical Center, Omaha, NE 68198
9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, 
Los Angeles, CA 90095
10Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, Toronto, Ontario M5T 3L9, Canada
11Department of Medicine and 12Keenan Research Centre, Li Ka Shing Knowledge Institute, St. Michael’s Hospital, Toronto, 
Ontario M5B 1W8, Canada
A common feature among all forms of diabetes mellitus is a functional -cell mass insuf-
ficient to maintain euglycemia; therefore, the promotion of -cell growth and survival is a 
fundamental goal for diabetes prevention and treatment. Evidence has suggested that 
erythropoietin (EPO) exerts cytoprotective effects on nonerythroid cells. However, the 
influence of EPO on pancreatic  cells and diabetes has not been evaluated to date. In this 
study, we report that recombinant human EPO treatment can protect against diabetes 
development in streptozotocin-induced and db/db mouse models of type 1 and type 2 
diabetes, respectively. EPO exerts antiapoptotic, proliferative, antiinflammatory, and angio-
genic effects within the islets. Using -cell–specific EPO receptor and JAK2 knockout mice, 
we show that these effects of EPO result from direct biological effects on  cells and that 
JAK2 is an essential intracellular mediator. Thus, promotion of EPO signaling in  cells may 
be a novel therapeutic strategy for diabetes prevention and treatment.
© 2010 Choi et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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To  assess  the   
effects of rHuEPO 
on diabetes protec-
tion, we first admin-
istered rHuEPO in 
an MLDS model of type 1 diabetes (Like and Rossini, 1976). 
rHuEPO or saline was administered to 6–8-wk-old C57BL/6 
mice three times weekly for 4 wk starting on the first day of 
STZ treatment. In contrast to the saline-treated controls that 
developed hyperglycemia within 1 wk after the start of STZ 
injections, the rHuEPO-treated group maintained euglycemia 
throughout the treatment period (Fig. 1 A). Fasting blood glu-
cose levels were also significantly reduced in the rHuEPO-
treated group compared with the saline-injected control 
group (Fig. 1 B). Theoretically, the lower blood glucose levels 
in the rHuEPO treatment group could be attributed to either 
increased peripheral insulin sensitivity or beneficial effects of 
rHuEPO directly on the  cells. The peripheral insulin sensi-
tivity was not increased, as assessed by insulin tolerance tests 
in the rHuEPO-treated mice (Fig. 1 C). Therefore, these 
results suggest that rHuEPO may have a direct role on the 
 cells to provide protection against STZ-induced diabetes.
Indeed, we observed that rHuEPO treatment in the MLDS 
model of diabetes led to an increase in -cell area (Fig. 2 A). 
To investigate the cellular mechanism responsible for the pro-
tective role of rHuEPO against STZ-induced diabetes, we   
examined for -cell proliferation and apoptosis by Ki67 
immunostaining and terminal deoxynucleotidyl transferase 
dUTP nick end labeling (TUNEL), respectively. There was an 
increase in Ki67-positive  cells (Fig. 2 B and Fig. S2 A) and a re-
duction in TUNEL-positive cells in the islets of the rHuEPO-
treated group compared with saline-treated mice (Fig. 2 C and 
Fig. S2 B). EPO has also been shown to provide cytoprotec-
tion through angiogenesis. To assess the vasculature, we exam-
ined for the presence of factor VIII (Fig. 2 D) and CD31 
(Fig. 2 E and Fig. S2 C), both endothelial cell markers which 
were present in higher concentrations within the islets of mice 
in the rHuEPO-treated group compared with saline-injected 
controls. Quantitative real-time PCR analyses showed enhanced 
bcl-xL and vascular endothelial growth factor (vegf) mRNA levels 
in isolated islets of rHuEPO-treated mice compared with   
saline-treated controls in the STZ-treated cohort (Fig. 2 F). 
These results are in keeping with the inhibition of apoptosis 
and enhanced angiogenesis observed from histological analy-
ses of the islets of rHuEPO-treated mice. We also observed a sig-
nificant attenuation in the induction of IL-1, TNF, IL-6, and 
MCP-1 (monocyte chemotactic protein-1) transcript levels in 
islets has been shown to prevent cytokine-induced cell death 
(Fenjves et al., 2004). (b) EPO deficiency and a higher inci-
dence of anemia have been shown in individuals with diabetes, 
suggesting potential beneficial effects of EPO in the setting of 
diabetes (Craig et al., 2005; McGill and Bell, 2006; Thomas, 
2006). (c) In a recent major clinical trial involving individuals 
without diabetes with chronic renal failure, EPO treatment 
was associated with a significant increase in the incidence of 
hypoglycemia as an adverse effect, which raises the intriguing 
possibility of a direct effect of EPO on pancreatic  cells 
(Drüeke et al., 2006). (d) EPO-R belongs to the cytokine 
class I receptor superfamily and utilizes a similar signal trans-
duction pathway as the receptors for growth hormone and 
prolactin, knockouts of which show defects in -cell mass 
and function (Freemark et al., 2002; Liu et al., 2004). Collec-
tively, these data raise the possibility that EPO signaling may 
have significant biological effects on  cells and thus may be 
relevant to diabetes.
Mechanistically, EPO binding to the EPO-R leads to the 
activation of downstream signaling pathways, including the 
canonical  JAK2–STAT5  pathway,  in  addition  to  phosphati-
dylinositol-3 kinase (PI3K) and Ras–mitogen-activated protein 
kinase pathways (Damen et al., 1993; He et al., 1993; Quelle 
et al., 1996). The JAK2–STAT5 pathway leads to the transcrip-
tion of STAT5-dependent genes that are involved in prolifera-
tion, survival, and angiogenesis (Bittorf et al., 2000; for review 
see Brines and Cerami, 2006). These EPO-mediated signaling 
pathways are well characterized for the erythroid cell types but 
are less well defined for the other nonerythroid tissues.
In this study, we investigated the in vivo protective role of 
EPO against the multiple low doses of streptozotocin (STZ 
[MLDS]) model of type 1 diabetes and the db/db mouse model 
of type 2 diabetes. Administration of recombinant human 
EPO (rHuEPO) resulted in diabetes prevention and reversal 
in both models of diabetes. Diabetes protection was caused by 
the direct effects of EPO on the pancreatic  cells in promot-
ing antiapoptosis, proliferation, and angiogenesis within the 
pancreatic islets, signaling through its cognate receptor and its 
downstream effector, JAK2.
RESULTS
rHuEPO protects mice against STZ-induced type 1 diabetes
EPO-R messenger RNA (mRNA) and protein are present in 
isolated islets, pancreas, brain, liver, and kidney of mice as shown 
by RT-PCR and Western blot, respectively (Fig. S1, A and B). 
We also confirmed the expression of EPO-R by quantitative 
real-time PCR in FACS-sorted pancreatic  cells (Fig. S1 C).
Figure 1.  Treatment with rHuEPO pro-
tects against hyperglycemia in the MLDS 
model of diabetes. (A) 6–8-wk-old C57BL/6 
mice were injected with rHuEPO or saline 
three times per week for 4 wk starting on 
the first day of STZ treatment. Blood glucose 
levels were measured at the indicated time 
points (n = 15 per treatment group). (B) Fast-
ing blood glucose levels were measured after 
4 wk of rHuEPO or saline treatment (n = 10 
per treatment group). (C) Insulin tolerance 
(insulin sensitivity) was measured after 4 wk 
of treatment (n = 6 per treatment group).  
*, P < 0.05. Results represent means ± SE.JEM VOL. 207, December 20, 2010 
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able  to  reverse  STZ-induced  diabetes 
(Fig.  S2  H).  2  wk  after  the  start  of 
STZ injections, we observed a signifi-
cant decrease in -cell area in the STZ-
treated mice compared with control mice 
treated with citrate buffer, as assessed 
by insulin-immunostained pancreatic 
sections (Fig. S2 I). Mice treated with 
rHuEPO 2 wk after STZ, after devel-
opment  of  diabetes,  had  enhanced   
-cell area compared with saline-treated 
mice after 4 wk of treatment (Fig. S2 J), 
which indicates that rHuEPO treat-
ment is able to reverse STZ-mediated 
-cell destruction.
rHuEPO treatment reverses hyperglycemia in the db/db 
mouse model of type 2 diabetes
We also examined the protective effects of rHuEPO against 
diabetes in the db/db (leptin receptor mutant) mouse model 
of type 2 diabetes. 5-wk-old male db/db mice were treated 
with rHuEPO, at which time severe diabetes was already 
present (>25 mmol/l). Blood glucose levels in the rHuEPO 
treatment group decreased promptly and remained lower com-
pared with those in the saline-treated control group through-
out the treatment period (Fig. 3 A). Fasting blood glucose 
levels were also significantly reduced in the rHuEPO-treated 
islets of mice in response to STZ in the rHuEPO-treated 
compared with the saline-treated group (Figs. S2, D–G). These 
results suggest that rHuEPO also has the role of dampening 
the inflammatory response at the level of the islet in the con-
text of STZ-induced diabetes. Finally, analysis of insulin and 
glucagon double immunostaining on pancreatic sections 
showed intact islet architecture in both the rHuEPO- and   
saline-treated mice (Fig. 2 G).
We assessed whether rHuEPO treatment can reverse es-
tablished diabetes by starting rHuEPO treatment 2 wk after 
the start of STZ injections. We observed that rHuEPO was 
Figure 2.  rHuEPO-treated mice have  
enhanced -cell mass. (A) -cell area per  
pancreatic area was determined on  
insulin-immunostained sections (n = 11 per 
treatment group). (B) -cell proliferation was 
assessed on Ki67/insulin-coimmunostained  
sections (n = 11 per treatment group). (C) TUNEL-
positive apoptotic  cells were determined on 
the day after the last STZ injection (n = 3 per 
treatment group). (D and E) Islet vasculature  
was assessed on factor VIII (D)– and CD31  
(E)-immunostained pancreatic sections (n = 5 per 
treatment group). Mice were sacrificed after  
4 wk of treatment. (F) bcl-xL and vegf mRNA 
levels in isolated islets were assessed by quanti-
tative real-time PCR after 1 wk of STZ and either 
rHuEPO or saline treatments (n = 3 per treat-
ment group). The expression level of each un-
known was normalized by the internal control 
18S. Each sample was run in triplicate, and each 
experiment included three nontemplate control 
wells. Similar results were also found from the 
normalization by GAPDH and actin (not de-
picted). (G) Intact islet architecture in both 
rHuEPO- and saline-treated mice as assessed by  
insulin (red) and glucagon (green) coimmuno-
staining (n = 3 per treatment group). Mice were 
sacrificed after 4 wk of their respective treat-
ments. *, P < 0.05. Results represent means ± SE. 
Bars: (A) 200 µm; (D) 20 µm; (G) 40 µm.2834 Erythropoietin protects against diabetes in mice | Choi et al.
rHuEPO administration improves glucose 
homeostasis under basal conditions
Having  demonstrated  the  protective  effects  of 
EPO in both type 1 and type 2 diabetes models, 
we next assessed whether rHuEPO had direct   
effects on pancreatic islets under basal physiological 
conditions.  Interestingly,  rHuEPO  had  glucose-
lowering effects even in nondiabetic conditions, 
as assessed by random glucose levels (Fig. S3 A). 
Importantly, the rHuEPO-treated mice did not 
develop hypoglycemia, which suggests that rHuEPO is able 
to enhance -cell secretion while maintaining glucose re-
sponsiveness. Their  fasting  blood  glucose  levels  were  also 
lower after 4 wk of rHuEPO treatment (Fig. S3 B). To assess 
for changes in peripheral insulin sensitivity, we performed in-
sulin tolerance tests (Fig. S3 C). These tests revealed that the 
glucose-lowering effects of rHuEPO were not caused by an 
increase in whole-body insulin sensitivity but likely caused by 
biological effects of rHuEPO on the pancreatic  cells. These 
observations further suggest that the improved glucose homeo-
stasis in the rHuEPO-treated mice is primarily caused by the 
direct biological effects of rHuEPO on the pancreatic  cells.
To further examine whether rHuEPO plays a role in the 
dynamic process of -cell homeostasis under basal conditions, 
we examined the pancreata of C57BL/6 mice treated with 
rHuEPO for 4 wk. -cell area per pancreatic area was increased 
in the rHuEPO-treated mice compared with the saline-treated 
group (Fig. S3 D), likely because of the increase in the per-
centage of Ki67-positive  cells observed in rHuEPO-treated 
mice (Fig. S3 E). Analyses of factor VIII and CD31 immuno-
staining showed enhanced vasculature in the islets of the 
rHuEPO-treated mice compared with control mice (Fig. S3, 
F and G). rHuEPO treatment did not appear to have an effect 
on islet morphology (Fig. S3 H). In addition, we observed a 
significant increase in the hematocrit in the rHuEPO-treated 
mice compared with controls, which reflects the expected bi-
ological effect of EPO on erythropoiesis (Fig. S4).
Exogenous EPO signals through the JAK2–STAT5  
and PI3K–Akt pathway in  cells
To assess for potential molecular mechanisms responsible for 
the effect of EPO in pancreatic  cells, we isolated islets from 
rHuEPO-treated mice and measured their transcript levels of 
bcl-xL, a major target gene in response to STAT5 activation in 
group compared with controls (Fig. 3 B). Similar to the ex-
periment in the MLDS model, the improved glucose ho-
meostasis  in  the  rHuEPO-treated  db/db  mice  was  not 
caused by an increase in insulin sensitivity, as indicated by 
the results of insulin tolerance tests (Fig. 3 C). We then ex-
amined for -cell area in the two treatment groups in the 
db/db cohort. There was a statistically significant increase in 
-cell area per pancreatic area in the rHuEPO-treated mice 
compared with saline-treated controls (Fig. 4 A). Assessment 
of Ki67-positive cells showed no differences between the 
rHuEPO- and saline-treated db/db mice (Fig. 4 B). This 
may be because of the fact that islet proliferation in db/db 
mice was already enhanced in response to severe peripheral 
insulin resistance (DeFronzo, 1997), such that EPO may not 
have provided a significant additional proliferative stimulus.   
However, we did observe a decrease in TUNEL-positive  cells 
on pancreatic sections of the rHuEPO-treated db/db mice 
(Fig. 4 C), which is suggestive of decreased apoptosis to   
account for the increased -cell mass in the rHuEPO-treated 
db/db mice. In addition, rHuEPO treatment in the db/db 
mice enhanced blood vessel density in the islets as assessed 
by factor VIII and CD31 staining on pancreatic sections, 
which is suggestive of enhanced islet oxygenation (Fig. 4, 
D and E). Furthermore, there was a significant increase in 
bcl-xL and vegf mRNA levels in the islets of rHuEPO-treated 
db/db mice compared with saline-treated controls, as as-
sessed by quantitative real-time PCR (Fig. 4 F). Interest-
ingly, glucose-stimulated insulin secretion was increased in 
the rHuEPO-treated db/db mice compared with controls 
(Fig. 3 D), which is suggestive of a role for EPO in en-
hancing  -cell  function,  perhaps  through  promoting   
-cell viability in db/db mice. Finally, islet morphology   
was  normal  in  both  rHuEPO-  and  saline-treated  db/db 
mice staining (Fig. 4 G).
Figure 3.  Treatment with rHuEPO reverses type 2 
diabetes in the db/db mouse. (A) Random blood glucose 
levels were measured weekly (n = 10 per treatment group). 
(B) Fasting blood glucose levels were measured after 4 wk 
of treatment (n = 10 per treatment group). (C) Insulin sen-
sitivity as assessed by insulin tolerance tests performed  
after 4 wk of treatment (n = 10 per treatment group).  
(D) In vivo glucose-stimulated insulin secretion was performed 
after 4 wk of rHuEPO or saline treatment (n = 9 per treat-
ment group). *, P < 0.05. Results represent means ± SE.JEM VOL. 207, December 20, 2010 
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EPO in angiogenesis, we measured 
mRNA levels of vegf, which was in-
creased in response to rHuEPO.
EPO  has  been  shown  to  use 
multiple intracellular signaling path-
ways in promoting tissue protection, 
including the JAK2–STAT5, PI3K–
Akt, and mitogen-activated protein 
kinase pathways, although the JAK–
STAT pathway is considered to be 
the  principal  signal  downstream  of 
EPO (Bittorf et al., 2000; for review 
see Brines and Cerami, 2006). To   
determine the intracellular signal-
ing proteins in response to rHuEPO 
treatment in vivo, we treated C57BL/6 mice with rHuEPO 
for 1 wk and isolated islets to examine for proteins in the 
EPO-R signaling cascade. Phospho-JAK2, phospho-STAT5, 
and  Bcl-xL  expression  was  increased  in  the  islets  of  the 
rHuEPO-treated group (Fig. 5 B), showing that EPO elicits 
its effects on the pancreatic  cells through the JAK2–STAT5–
Bcl-xL pathway. The PI3K–Akt pathway has also been impli-
cated in EPO-mediated tissue protection (Leverrier et al., 1999),   
and this pathway has been reported to play a major role in   
-cell growth and survival (Bernal-Mizrachi et al., 2001, 2004; 
Nguyen et al., 2006; Stiles et al., 2006). We found that rHuEPO 
treatment resulted in increased Akt phosphorylation in  cells 
providing antiapoptotic effects of EPO (Bittorf et al., 2000). 
bcl-xL mRNA levels were significantly increased in the islets 
of rHuEPO-treated mice (Fig. 5 A). Expression of c-myc, a 
STAT target gene which has potent proliferative effects, was 
increased in isolated islets in response to systemic rHuEPO 
treatment (Fig. 5 A). We also found an increase in mRNA 
transcript levels of c-kit in the isolated islets of rHuEPO-
treated mice (Fig. 5 A). c-kit is a well-known stem cell marker 
that is present in regenerating pancreatic  cells after islet de-
struction (Tiemann et al., 2007). These findings suggest that 
rHuEPO may promote antiapoptotic and proliferative effects 
on  cells through these target genes. To analyze the role of 
Figure 4.  Effect of rHuEPO treatment 
on the islets of db/db mice. (A) -cell area  
per pancreatic area was calculated on  
insulin-immunostained pancreatic sections  
(n = 10 per treatment group). (B and C) The 
percentage of Ki67-positive proliferating  
 cells (B) and TUNEL-positive apoptotic  
 cells (C) per islet was assessed by immuno-
histochemistry (n = 10 per treatment group). 
(D and E) Islet vasculature was assessed by 
factor VIII (D) and CD31 (E) immunostaining 
on pancreatic sections (n = 5 per treatment 
group). Mice were sacrificed after 4 wk of 
treatment. (F) bcl-xL and vegf mRNA levels 
in isolated islets after 1 wk of rHuEPO or 
saline treatment were assessed by quantita-
tive real-time PCR (n = 3 per treatment 
group). The expression level of each un-
known was normalized by the internal con-
trol 18S. Each sample was run in triplicate, 
and each experiment included three non-
template control wells. Similar results were 
also found from the normalization by 
GAPDH and actin (not depicted). (G) Insulin 
(red) and glucagon (green) coimmunostain-
ing was performed to determine islet archi-
tecture (n = 3 per treatment group). Mice 
were sacrificed after 4 wk of treatment.  
*, P < 0.05. Results represent means ± SE. 
Bars: (A) 200 µm; (D and G) 40 µm.2836 Erythropoietin protects against diabetes in mice | Choi et al.
22.35  ±  1.79  fF/pF  in  saline-treated  cells; 
Fig. S5 E). These results suggest that rHuEPO 
does not have direct enhancing effects on the 
insulin secretion machinery but rather pro-
vides  diabetes  protection  through  the  en-
hancement of islet mass and viability.
EPO-R in the  cells is not required for glucose homeostasis 
under basal conditions
To further assess the direct effects of EPO on pancreatic  cells, 
we next took a genetic approach by assessing -cell–specific 
EPO-R knockout mice (Fig. S6, A–C). We first assessed 
whether endogenous EPO action on  cells would have a 
direct impact in basal glucose homeostasis by measuring ran-
dom and fasting blood glucose levels in the mice at 1 and   
2 mo of age. Our results show that there were no differences   
in both measurements between the RIPcre+EpoR+/+ and 
RIPcre+EpoRfl/fl mice (Fig. S6, D and E). Furthermore, glu-
cose and insulin tolerance tests revealed no significant differ-
ences between the genotypes (Fig. S6, F and G), suggesting 
that -cell EPO-R does not play an essential role in the main-
tenance of glucose homeostasis in vivo. Similarly, there were 
no differences in -cell mass and islet morphology between 
the RIPcre+EpoR+/+ and RIPcre+EpoRfl/fl mice at 2 mo of age 
(Fig. S6, H and I). These findings demonstrate that endog-
enous EPO signaling in  cells is not essential in regulating 
-cell mass under homeostatic conditions.
EPO-R is required for rHuEPO-mediated diabetes protection 
against the MLDS model of type 1 diabetes
We next assessed whether direct effects of EPO in pancreatic 
 cells were essential for the diabetes protection provided by 
exogenous EPO. RIPcre+EpoRfl/fl mice and their control   
littermates were subjected to MLDS-induced diabetes while 
on either rHuEPO or saline treatment. In contrast to the 
RIPcre+EpoR+/+ mice, which were protected against STZ- 
induced diabetes while on rHuEPO treatment (Figs. 1 A and 
6 A), diabetes protection was not observed in rHuEPO-
treated RIPcre+EpoRfl/fl mice (Fig. 6 A). Similarly, pancreatic 
morphometry analyses showed enhanced -cell area per   
(Fig. 5 B). In keeping with the observation of enhanced 
insulin signaling, the islets of rHuEPO-treated mice showed 
greater expression of PDX-1 (pancreatic and duodenal ho-
meobox 1), a downstream transcriptional target of insulin sig-
naling which is important for -cell growth and differentiation 
(Fig. 5 B; Kulkarni et al., 2004). Furthermore, GLUT2, a 
-cell differentiation marker which is important for glucose 
sensing, was also increased in the islets of rHuEPO-treated mice 
compared with controls (Fig. 5 B).
Ex vivo effects of rHuEPO on -cell function
To assess whether EPO may have direct effects on -cell 
function,  which  may  account  for  the  improved  glucose-
stimulated insulin secretion in the rHuEPO-treated db/db 
mice, we performed islet perifusion experiments and exam-
ined for changes in membrane capacitance on individual   
 cells. Our results showed similar insulin secretion between 
the islets treated with rHuEPO or saline in response to high 
glucose (16.7 mM) or KCl during perifusion of individual 
islets (Fig. S5, A and B). By patch-clamp capacitance mea-
surements on individual  cells, we assessed for changes in 
membrane capacitance (Fig. S5, C–E). The first two depo-
larization pulses, which determine the initial readily re-
leasable pool of insulin granules, or first phase of insulin 
secretion, showed no difference in membrane capacitance of 
rHuEPO-treated  cells (6.89 ± 1.70 fF/pF) compared with 
control cells (6.47 ± 0.88 fF/pF). Similarly, the incremental 
and cumulative increases in cell membrane capacitance be-
tween the 3rd and 10th pulses, which measure the rate of 
insulin granule mobilization to the releasable pool, or the 
second phase of insulin secretion, also showed similar in-
crements between the rHuEPO-treated and saline-treated   
 cells (20.13 ± 4.25 fF/pF in rHuEPO-treated  cells vs. 
Figure 5.  Effect of rHuEPO administration on 
islet signaling and gene transcription. (A) Quantita-
tive real-time PCR results of bcl-xL, c-myc, c-kit, and 
vegf mRNA levels in islets isolated after 1 wk of rHuEPO 
treatment (n = 3 per treatment group). The expression 
level of each unknown was normalized by the internal 
control 18S. Each sample was run in triplicate, and each 
experiment included three nontemplate control wells. 
Similar results were also found from the normalization 
by other internal controls, including GAPDH and actin 
(not depicted). (B) Western blots of islet protein lysates 
were performed after 1 wk of rHuEPO or saline admin-
istration to assess phospho (p)-JAK2, phospho-STAT5, 
and Bcl-xL expression levels as well as phospho-AKT, 
PDX-1, and GLUT2 levels (n = 3 per treatment group).  
*, P < 0.05. Results represent means ± SE.JEM VOL. 207, December 20, 2010 
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Direct effects of rHuEPO on pancreatic  cells for target 
gene regulation
rHuEPO treatment in mice was shown to enhance the ex-
pression of bcl-xL, c-myc, c-kit, and vegf in isolated islets (Fig. 5). 
To  determine  whether  the  enhanced  expression  of  these 
genes in isolated islets was caused by direct effects of rHuEPO 
on the pancreatic  cells, we treated RIPcre+EpoR+/+ and 
pancreatic  area  in  the  rHuEPO-treated  RIPcre+EpoR+/+ 
mice, but this effect of rHuEPO on pancreatic  cells was 
abolished in the RIPcre+EpoRfl/fl mice (Fig. 6, B and C). Fur-
thermore, the increase in Ki67-positive  cells (Fig. 6 D) and 
increase in islet vasculature observed in the rHuEPO-treated 
RIPcre+EpoR+/+  mice  were  also  abolished  in  islets  of 
RIPcre+EpoRfl/fl mice (Fig. 6, E and F).
Figure 6.  EPO-R is required for rHuEPO-mediated diabetes protection against STZ treatment. (A) Blood glucose levels were measured on a 
weekly basis throughout the treatment period (n = 8 per treatment group). (B and C) Insulin-immunostained pancreatic sections were performed to as-
sess -cell area per pancreatic area (n = 8 per treatment group). (D) Ki67 immunostaining on pancreatic sections was performed to assess the percentage 
of Ki67-positive  cells per islet (n = 8 per treatment group). (E and F) Islet vasculature was assessed by factor VIII immunostaining on pancreatic 
sections (n = 5 per treatment group). Mice were sacrificed 4 wk after their respective treatments. *, P < 0.05. Results represent means ± SE. Bars:  
(C) 200 µm; (F) 20 µm.2838 Erythropoietin protects against diabetes in mice | Choi et al.
of postprandial blood glucose levels (Fig. S8 A). In keeping 
with the lack of diabetes protection, RIPcre+Jak2fl/fl mice did not 
have a significant increase in -cell area per pancreatic area in 
response to rHuEPO treatments, in contrast to RIPcre+Jak2+/+ 
mice treated with rHuEPO, in which the increase was ob-
served (Fig. S8, B and C). Similarly, the increase in Ki67-positive 
 cells (Fig. S8 D) and increase in islet vasculature present in 
the rHuEPO-treated RIPcre+Jak2+/+ mice compared with 
saline-treated controls were absent in the islets of RIPcre+Jak2fl/fl 
mice (Fig. S8, E and F). These data, which parallel those of 
EPO-R mutant mice, collectively indicate that the rHuEPO-
mediated diabetes protection occurs through direct activation   
of EPO signaling in pancreatic  cells and that JAK2 is   
its essential mediator. Similarly, the islet gene modulation   
by rHuEPO appears to also be mediated through JAK2 in   
 cells. As such, bcl-xL, c-myc, c-kit, and vegf in the islets of   
rHuEPO-treated RIPcre+Jak2fl/fl mice were lower than those of   
RIPcre+  Jak2+/+ mice (Fig. S8 G).
DISCUSSION
Central to both type 1 and type 2 diabetes is a pancreatic   
-cell defect, as manifested by -cell death and dysfunction. 
rHuEPO was previously shown to have cytoprotective effects 
in nonerythroid tissues (for review see Brines and Cerami, 
2006); therefore, we investigated whether the cytoprotective 
effects of EPO extended to the pancreatic  cells in diabetes 
models. Intriguingly, we found that systemic rHuEPO admin-
istration confers diabetes protection by exerting a direct bio-
logical effect on  cells through its cognate receptor, EPO-R, 
and its immediate downstream kinase, JAK2, as we have dem-
onstrated using -cell–specific EPO-R and JAK2 knockout 
mice. Importantly, no other downstream kinase was able to 
compensate for JAK2 to mediate EPO-R signaling in  cells of 
the JAK2 knockout mice. Thus, our results show that pancre-
atic  cells may use similar EPO-mediated signaling machin-
ery as that which is used during embryogenesis, as indicated 
by the similar phenotypes of embryonic lethality caused by 
fetal anemia observed in both JAK2- and EPO-R–null mice 
(Wu et al., 1995; Neubauer et al., 1998).
It appears that the protective effect of rHuEPO on the 
 cells under diabetes conditions occurs largely through the 
promotion of -cell growth and survival rather than through 
direct effects on -cell function. Indeed, the islet perifusion and 
patch-clamp capacitance measurements show that rHuEPO 
does not have a significant enhancing effect on -cell func-
tion per se. Instead, our data show that rHuEPO treatment has 
antiapoptotic, proliferative, and angiogenic effects on the pan-
creatic islets.
The increase in bcl-xL expression induced by EPO may 
be the critical molecular mechanism through which EPO 
inhibits apoptosis in  cells during diabetes progression.   
A previous study has shown that increased bcl-xL  expression 
is a key mediator of EPO action in maintaining erythrocyte 
mass in an organism, as bcl-xL–null mice die embryonically 
as the result of anemia and defects in erythropoiesis (Motoyama 
et al., 1995). Furthermore, EPO has been shown to up-regulate 
RIPcre+EpoRfl/fl mice with rHuEPO for 1 wk and analyzed 
the expression of these genes in the isolated islets. Our results 
by RT-PCR showed that the islets of RIPcre+EpoRfl/fl mice 
treated with rHuEPO did not show an induction in these genes, 
and the gene levels were lower compared with rHuEPO-
treated RIPcre+EpoR+/+ mice (Fig. 7), which is indicative of 
the requirement of EPO-R in  cells for the transcriptional 
regulation by rHuEPO.
RIPcre+Jak2fl/fl mice have no defects in glucose homeostasis
JAK2 has been identified as a canonical essential intracellular 
mediator of EPO action in erythrocyte precursors; however, 
EPO-mediated signaling events in pancreatic  cells have re-
mained  elusive. Therefore,  we  assessed  -cell–specific  JAK2 
knockout mice (Fig. S7, A–C) to determine its essential role in 
EPO signaling in  cells. To assess for changes in glucose homeo-
stasis, we measured monthly fed and fasting blood glucose, 
which showed no differences between the RIPcre+Jak2fl/fl mice 
and their littermate controls (Fig. S7, D and E). Glucose and 
insulin tolerance tests also showed similar results between the 
mutant mice and their littermate controls (Fig. S7, F and G).
JAK2  is  described  to  function  downstream  of  various 
growth factors, including growth hormone, prolactin, and pla-
cental lactogen, which have all been shown to play an essential 
role in pancreatic -cell homeostasis (Sorenson and Stout, 
1995; Cousin et al., 1999; Fujinaka et al., 2007). Surprisingly, 
analyses of insulin-immunostained pancreatic sections revealed 
no differences in -cell area per pancreatic area and islet 
architecture in the RIPcre+Jak2fl/fl mice compared with those 
of control RIPcre+Jak2+/+ littermates (Fig. S7, H and I).
JAK2 in pancreatic  cells is required for diabetes 
protection by rHuEPO
RIPcre+Jak2fl/fl and control mice were subjected to STZ-
induced diabetes with or without rHuEPO treatment to as-
sess for the essential direct role of JAK2 in EPO signaling 
in pancreatic  cells. rHuEPO provided protection in the 
RIPcre+Jak2+/+ mice; however, diabetes protection was not ob-
served in the RIPcre+Jak2fl/fl mice, as assessed by measurements 
Figure 7.  Role for EPO-R in EPO-mediated gene transcription in 
islets. Quantitative real-time PCR was performed to measure expression 
levels of bcl-xl, c-kit, c-myc, and vegf in isolated islets after 1 wk of 
rHuEPO or saline treatment (n = 3 per genotype). The expression level of 
each unknown was normalized by the internal control 18S. Each sample 
was run in triplicate, and each experiment included three nontemplate 
control wells. Similar results were also found from the normalization by 
GAPDH and actin (not depicted). *, P < 0.05. Results represent means ± SE.JEM VOL. 207, December 20, 2010 
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Harlan Teklad) and housed in pathogen-free barrier facilities at the central 
animal facility in the Ontario Cancer Institute (Toronto, Ontario, Canada). 
All animal experiments were approved by the Ontario Cancer Institute 
Animal Care Facility.
rHuEPO  treatment.  rHuEPO  (Epoetin-;  Eprex;  Ortho-Biotech)  was 
used. Mice were injected i.p. three times per week at a dose of 50 µg/kg body 
weight (Savino et al., 2006) between 9 a.m. and 10 a.m.
Hematocrit measurement. 30 µl of tail vein blood was collected using 
EDTA-coated capillary tubes. Samples were kept at room temperature before 
analysis at the Toronto Centre for Phenogenomics (Toronto, Ontario, Canada).
STZ protocol. MLDS were i.p. injected into mice (40 mg/kg body weight) 
for a consecutive 5 d (Liadis et al., 2005). Blood glucose was measured weekly 
after i.p. MLDS injections from tail vein blood with an automated glucose 
monitor (Precision Xtra; Abbott Laboratories).
Metabolic experiments and hormone measurements. Overnight fasts 
were 14–16 h in duration. Glucose tolerance tests were performed on over-
night-fasted animals using a glucose dose of 1 g/kg body weight injected i.p., 
and measurements of blood glucose were taken at 0, 15, 30, 45, 60, and   
120 min after the injection. Insulin tolerance tests were performed using   
human regular insulin (Novo Nordisk) at a dose of 1 U/kg body weight, and 
blood glucose levels were measured at 0, 15, 30, 45, 60, and 120 min after the 
injection of insulin. Glucose-stimulated insulin secretion in vivo was per-
formed on overnight-fasted animals after an i.p. injection of glucose at a dose 
of 3 g/kg body weight, with tail vein blood collected at 0, 2, 10, and 30 min 
after the injection. Insulin levels were measured by an ELISA kit using a rat 
insulin standard (Crystal Chem Inc.).
Islet  morphometry,  immunohistochemistry,  and  immunofluores-
cent staining. Pancreatic tissue was fixed for 24 h in 4% paraformaldehyde 
in 0.1 M phosphate-buffered saline, pH 7.4. 7-µm-thick paraffin sections 
were obtained at 150-µm intervals on three levels and stained for insulin, 
glucagon, Ki67, factor VIII (Dako), and CD31 (Santa Cruz Biotechnology, 
Inc.). TUNEL (ID Labs) was performed by immunohistochemistry. Immuno-
fluorescence  was  visualized  using  an  inverted  fluorescent  microscope   
(Axio Observer; Carl Zeiss, Inc.). Insulin- and factor VIII–immunostained 
sections were scanned using a ScanScope ImageScope system and analyzed 
with ImageScope version 9.0.19.1516 software (Aperio Technologies). Fac-
tor  VIII immunostaining was calculated per -cell area by an automated posi-
tive pixel count algorithm. Total -cell area per total pancreatic area was 
determined on insulin-stained sections.
Islet isolation and -cell sorting. Islets were isolated from mice as previ-
ously described (Liadis et al., 2005). In brief, 3 ml of 3 mg/ml collagenase 
(Sigma-Aldrich) was injected into the common bile duct for pancreatic di-
gestion. Isolated islets were maintained in suspension culture in RPMI 1640 
supplemented with 10% fetal bovine serum, 100 U/ml penicillin, and   
100 µg/ml streptomycin. For -cell sorting, freshly isolated islets were dis-
persed and subjected to flow cytometry based on high autofluorescence, as 
previously described (Allison et al., 2005; Liadis et al., 2007).
Islet perifusion secretory assay. Islets were isolated from C57BL/6 mice 
as previously described (Liadis et al., 2005) and incubated overnight in either 
100 U/ml rHuEPO or saline. The next day, batches of 50 islets, on average, 
per group were placed in 37°C perifusion chambers (with rHuEPO for the 
rHuEPO-treated islets) and perifused at a flow rate of 1 ml/min with a 
Krebs-Ringer bicarbonate buffer. Islets were initially equilibrated for 30 min 
in Krebs-Ringer bicarbonate Hepes buffer supplemented with 2.8 mmol/l 
glucose. They were then stimulated with 2.8 mmol/l glucose for 10 min, 
which was followed by stimulation with 16.7 mmol/l glucose for 40 min. 
After 40 min with 16.7 mmol/l glucose alone, the islets were subjected to an 
additional 25-min stimulation period with 30 mmol/l KCl. Fractions were 
bcl-xL expression in various erythroleukemic cells lines (Silva 
et al., 1999).
We have also shown that rHuEPO treatment increases   
-cell proliferation as well as enhances the transcription of 
c-myc and c-kit. EPO has been previously shown to induce the 
proliferation and expression of c-myc in normal human ery-
throid progenitors (Umemura et al., 1988). In addition, c-kit 
has been reported to be present on progenitor cells of the 
pancreas and play an important role during pancreatic devel-
opment and during regeneration after STZ-induced diabetes 
(Tiemann et al., 2007). Furthermore, a recent study has also 
shown a physiological role of c-kit in the growth and mainte-
nance of -cell mass in mice (Krishnamurthy et al., 2007). 
Therefore, c-kit may be an important mediator through which 
effects of rHuEPO on pancreatic  cells are achieved.
Furthermore, rHuEPO administration increases vegf ex-
pression in the pancreatic islets, and EPO-mediated angio-
genesis in the islets is dependent on -cell EPO-R and JAK2. 
Islets are highly vascular, and previous work has shown that 
the dense vasculature is dependent on VEGF that is produced 
by the pancreatic  cells (Lammert et al., 2003). VEGF is 
known to play an essential role in maintaining the integrity of 
the microvasculature and in stimulating angiogenesis to aid in 
tissue healing (Ribatti et al., 2003; Galeano et al., 2004).  VEGF 
has been shown to increase not only oxygenation and nutri-
ent delivery to the islets but also to have a direct impact on 
pancreatic -cell function by mechanisms that are not yet en-
tirely clear (Heeschen et al., 2003). Given the potent effect of 
rHuEPO on the up-regulation of  VEGF within islets, this im-
portant angiogenic factor may be another key mediator through 
which EPO promotes the survival and maintenance of func-
tion of pancreatic  cells.
Collectively, our in vivo data demonstrate potent protec-
tive effects of EPO against diabetes development by direct 
actions of EPO on  cells, thereby increasing -cell mass 
through antiapoptotic, proliferative, and angiogenic mecha-
nisms. In the context of the central role of -cell insufficiency 
in the pathogenesis of diabetes, these biological effects of EPO 
reflect ideal properties for a potential new therapeutic agent 
for diabetes. Indeed, EPO is a safe, widely used hormone, 
and strategies to generate nonerythropoietic EPO-related 
agents are currently being actively investigated. Thus, further 
understanding of the biology of EPO may hold promise for 
the development of a potential novel strategy for diabetes pre-
vention and treatment.
MATERIALS AND METHODS
Mice. Experiments were performed on 6–8-wk-old C57BL/6 mice and   
5-wk-old db/db mice in the C57BLKS/J background obtained from The 
Jackson Laboratory. RIPcre+ (Postic et al., 1999) and EpoRfl/fl (Tsai et al., 2006) 
or Jak2fl/fl (Wagner et al., 2004) mice were bred to generate RIPcre+EpoR+/fl 
(or Jak2+/fl) mice, which were then intercrossed to generate RIPcre and 
RIPcre+EpoR+/+(or Jak2+/+), RIPcre+EpoR+/fl (or Jak2+/fl), and RIPcre+EpoRfl/fl 
(or Jak2fl/fl) mice. These mice were examined at 8 wk of age and maintained on 
a 129J-C57BL/6-FVB/N mixed background, and RIPcre+EpoR+/+ (or Jak2+/+) 
littermates were used as controls. Mice were maintained on a 12-h light–dark 
cycle with free access to water and standard irradiated rodent chow (5% fat;   2840 Erythropoietin protects against diabetes in mice | Choi et al.
Online supplemental material. Fig. S1 shows the expression of EPO-R 
in pancreatic  cells and islets. Fig. S2 shows the effects of rHuEPO on STZ-
induced diabetes. Fig. S3 demonstrates the improvement of glucose homeo-
stasis as a result of rHuEPO treatment. Fig. S4 shows increased hematocrit   
in mice treated with rHuEPO compared with saline-treated mice. Fig. S5 
demonstrates  that  rHuEPO  does  not  have  an  effect  on  -cell  function.   
Fig. S6 shows that EPO-R is not required for glucose homeostasis. Fig. S7 
shows that JAK2 is not essential for glucose homeostasis under basal condi-
tions. Fig. S8 demonstrates that -cell JAK2 is required for rHuEPO-mediated 
protection against STZ-induced diabetes. Online supplemental material is 
available at http://www.jem.org/cgi/content/full/jem.20100665/DC1.
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